Screener
Syndax Pharmaceuticals SNDX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $472,668 | $529,706 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $10,843 | $16,580 |
| Accrued expenses and other current liabilities | 74,843 | 103,064 |
| Current portion of right-of-use liability | 487 | 470 |
| Current portion of capital lease | 1 | 2 |
| Total current liabilities | 86,174 | 120,116 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's accounts payable?
- Syndax Pharmaceuticals (SNDX) reported accounts payable of $10.84M in Q1 2026.
- How has Syndax Pharmaceuticals's accounts payable changed year-over-year?
- Syndax Pharmaceuticals's accounts payable increased by 7.9% year-over-year, from $10.05M to $10.84M.
- What is the long-term trend for Syndax Pharmaceuticals's accounts payable?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's accounts payable has grown at a 36.4% compound annual growth rate (CAGR), from $3.51M to $16.58M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Syndax Pharmaceuticals's accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude